An Innovative New Treatment Gives Hope to Women Who Have Difficulty Getting Pregnant

Food and Healthcare Press Releases Monday July 15, 2013 15:13
Bangkok--15 Jul--Spark Communications

MSD, one of the leading companies in the development of solutions in the IVF (In Vitro Fertilization) sector, has releaseda ground breaking new treatment for IVF patients which will make their lives a lot easier through a new fertility treatment.

This innovative new treatment gives hope to many women experiencing the emotional and physical stress of infertility issues, which is a sustained release follicle stimulating hormone (FSH) - the first of its kind. One significant benefit of using this new fertility treatment is the few number of treatments needed. Currently, women now undergoing IVF have to have a daily subcutaneous injection of FSH but this new solution means that they will only have to get an injection once a week.

This treatment is the first sustained follicle stimulant. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose may replace the first seven injections of any the conventional daily follicle stimulating hormone (FSH) injections for controlled ovarian stimulation (COS).

Today, up to 15%of couples globally experience fertility problems. In Thailand, fertility rates are in decline from 4.9 children per woman(1975) to 1.6 children per woman(2013), which is considered to be below the generally accepted level of 2.1 children to maintain current population levels. Infertility is a disease that impairs the body's ability to perform the basic function of reproduction. Many causes including problems with the production of sperm or eggs, with the fallopian tubes or the uterus, endometriosis, frequent miscarriage, as well as hormonal and autoimmune disorders in both men and women.

There are some treatments available for infertility, which include surgery, hormone treatments, insemination and IVF. But in the past treatments were time consuming and painful. MSD's new treatment provides an effective, easy, and patient-focused fertility treatment.

Dr. Somjate Manipalviratn, Clinical Director Obstetrician and Gynecologist as well as a leading reproductive endocrinology and infertility specialist, says: "The advent of this new fertility treatment marks a new era of hope for our patients. Infertility is a relatively common problem worldwide and in Thailand, and this new innovative treatment makes it much easier for both patients and doctors. The solutionis a positive step towards reducing the burden of daily injections for women experiencing difficulty conceiving."

Latest Press Release

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia(R) (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the...





Related Topics